The Cancer Letter

Inside information on cancer research and drug development

Guest Editorial

AAADV-ASCO-CDDF workshop to examine cancer prevention strategies in 2023

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
BYLINEDOWNLOAD PDFTABLE OF CONTENTS

Globally, about 18 million people will be diagnosed with cancer and approximately 10 million people will die from cancer this year. Between 30–50% of these cancer cases are potentially preventable today, a fact that highlights that prevention remains one of the most effective and cost-effective long-term strategies to reduce the global cancer burden. 

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Byline
H. Kim Lyerly, MD
George Barth Geller Distinguished Professor of Immunology, Professor of surgery, immunology, and pathology, Duke University School of Medicine
Renzo Canetta, MD
Former vice president, Global R&D oncology policy, Bristol-Myers Squibb Research and Development; Board member, Leukemia & Lymphoma Society
Philip E. Castle, PhD, MPH
Director, Division of Cancer Prevention, National Cancer Institute
Lisa M. McShane, PhD
Associate director, Division of Cancer Treatment and Diagnosis, National Cancer Institute
Richard L. Schilsky, MD
Professor emeritus, University of Chicago; Former chief medical officer, American Society of Clinical Oncology; Board chair, Reagan-Udall Foundation for FDA
Table of Contents

YOU MAY BE INTERESTED IN

In Brief

Kristen Doyle named CEO of CPRIT

Kristen Doyle was approved by the governing body of the Cancer Prevention and Research Institute of Texas as the agency’s new CEO beginning July 1. Doyle, currently deputy executive officer and general counsel, will succeed Wayne Roberts who will step down on June 30 after 12 years as chief executive.
Byline
H. Kim Lyerly, MD
George Barth Geller Distinguished Professor of Immunology, Professor of surgery, immunology, and pathology, Duke University School of Medicine
Renzo Canetta, MD
Former vice president, Global R&D oncology policy, Bristol-Myers Squibb Research and Development; Board member, Leukemia & Lymphoma Society
Philip E. Castle, PhD, MPH
Director, Division of Cancer Prevention, National Cancer Institute
Lisa M. McShane, PhD
Associate director, Division of Cancer Treatment and Diagnosis, National Cancer Institute
Richard L. Schilsky, MD
Professor emeritus, University of Chicago; Former chief medical officer, American Society of Clinical Oncology; Board chair, Reagan-Udall Foundation for FDA
Table of Contents

Login

Site license subscribers:
Log in with your IP | Register a sponsored account